gallbladder disease and semaglutide Ozempic: is a GLP-1 receptor agonist used for type 2 diabetes cardiovascular risk reduction in selected patients, commonly causing nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, and weight loss Semaglutide isn’t just a “weight-loss

The 2022 ASMBS/IFSO guidelines support consideration of metabolic surgery for patients with BMI 35 kg/m or 30 kg/m with obesity-related comorbidities

The Precision Peptide Genetic Test ($99 add-on after your first month) identifies whether your genetic variants in GLP1R (rs6923761), GIPR (rs1800437), or MC4R (rs17782313) predict higher or lower sensitivity to GLP-1 effects, including gastrointestinal side effects

The TRIUMPH-4 Phase 3 readout in April 2026 extended that to 28.7% at 68 weeks in a population with knee osteoarthritis - a patient group in whom weight loss produces disproportionate benefit on a secondary outcome (pain) the trial measured and reported as a 75.8% reduction on the WOMAC pain index

A concurrent blood glucose measurement was not required although most (74%) reports of hypoglycemia were accompanied by a blood glucose measurement 70 mg/dL

The backlash, according to Simpson, was immediate

Always carry in your carry-on never in checked luggage